tetano
Editor, Senior Moderator
J Med Virol
. 2025 Jan;97(1):e70133.
doi: 10.1002/jmv.70133. Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia
Myriam Arévalo-Herrera[SUP] 1 [/SUP], Bladimiro Rincón-Orozco[SUP] 2 [/SUP], John Mario González-Escobar[SUP] 3 [/SUP], Sonia Marcela Herrera-Arévalo[SUP] 1 [/SUP], Elena Carrasquilla-Agudelo[SUP] 1 [/SUP], Paula Andrea Serna-Ortega[SUP] 1 [/SUP], Sebastián Quiceno-García[SUP] 1 [/SUP], Nicolas Palacio-Muñoz[SUP] 1 [/SUP], Brandon Rosero-López[SUP] 1 [/SUP], Ernesto Mondol-Miranda[SUP] 1 [/SUP], Ivette Freyle-Roman[SUP] 2 [/SUP], Brayan Mendoza-Landinez[SUP] 2 [/SUP], Eliana Mora-Guevara[SUP] 2 [/SUP], Juan Carlos Santos-Barbosa[SUP] 3 [/SUP], Francisco Bohórquez-Martínez[SUP] 3 [/SUP], Natalia Bolaños-Cristancho[SUP] 3 [/SUP], Mónica Jiménez-Serna[SUP] 4 [/SUP], María A Nieto-Rojas[SUP] 4 [/SUP], David Suarez-Zamora[SUP] 4 [/SUP], Juliana Quintero-Espinosa[SUP] 4 5 [/SUP], Darío Londoño-Trujillo[SUP] 4 [/SUP], Sócrates Herrera-Valencia[SUP] 1 [/SUP]
Affiliations
A total of 5011 adult volunteers attending vaccination centers in different regions of Colombia were enrolled in a 1-year prospective observational cohort study to evaluate the immunogenicity and effectiveness of SARS-CoV-2-based vaccines as part of a National Vaccine Program established to contain the COVID-19 pandemic. Following informed consent, 5,011 participants underwent a sociodemographic survey and PCR testing to assess SARS-CoV-2 infection. Blood samples were collected, and serum fractions were obtained from a participant subsample (n = 3441) at six-time points to assess virus-specific IgG responses to the Spike protein, its Receptor Binding Domain, and the Nucleoprotein by ELISA. Additionally, antibody-neutralizing activity was evaluated using a cPass SARS-CoV-2 neutralization kit. Most participants (95.8%; n = 4802) received between one Ad26. COV2.S (Janssen vaccine) and four vaccine doses of BNT162b2 (Pfizer/BioNTech), AZD1222 (AstraZeneca), mRNA-1273 (Moderna), CoronaVac (Sinovac), with some receiving vaccine combinations; a small group, 4.2% (n = 209), remained unvaccinated. Throughout the study, only 8.76% (n = 439) of the participants tested positive for SARS-CoV-2 by PCR. Notably, all participants seroconverted for IgG antibodies, with high seropositivity rates for S (99.8%; n = 4795), RBD (99.7%; n = 1691), and N (92.7%; n = 3072) proteins. Moreover, significant (92%-97%) neutralizing activity was observed for all four SARS-CoV-2 circulating variants. This study highlights the importance of assessing the duration of the IgG response to SARS-CoV-2 elicited by vaccination and infection, and the antibody neutralizing activity as a potential surrogate marker of protection. These findings provide important insight for further strengthening the vaccination strategies to control COVID-19.
Keywords: COVID‐19; SARS‐CoV‐2; antibody; neutralization; vaccines.
. 2025 Jan;97(1):e70133.
doi: 10.1002/jmv.70133. Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia
Myriam Arévalo-Herrera[SUP] 1 [/SUP], Bladimiro Rincón-Orozco[SUP] 2 [/SUP], John Mario González-Escobar[SUP] 3 [/SUP], Sonia Marcela Herrera-Arévalo[SUP] 1 [/SUP], Elena Carrasquilla-Agudelo[SUP] 1 [/SUP], Paula Andrea Serna-Ortega[SUP] 1 [/SUP], Sebastián Quiceno-García[SUP] 1 [/SUP], Nicolas Palacio-Muñoz[SUP] 1 [/SUP], Brandon Rosero-López[SUP] 1 [/SUP], Ernesto Mondol-Miranda[SUP] 1 [/SUP], Ivette Freyle-Roman[SUP] 2 [/SUP], Brayan Mendoza-Landinez[SUP] 2 [/SUP], Eliana Mora-Guevara[SUP] 2 [/SUP], Juan Carlos Santos-Barbosa[SUP] 3 [/SUP], Francisco Bohórquez-Martínez[SUP] 3 [/SUP], Natalia Bolaños-Cristancho[SUP] 3 [/SUP], Mónica Jiménez-Serna[SUP] 4 [/SUP], María A Nieto-Rojas[SUP] 4 [/SUP], David Suarez-Zamora[SUP] 4 [/SUP], Juliana Quintero-Espinosa[SUP] 4 5 [/SUP], Darío Londoño-Trujillo[SUP] 4 [/SUP], Sócrates Herrera-Valencia[SUP] 1 [/SUP]
Affiliations
- PMID: 39817585
- DOI: 10.1002/jmv.70133
A total of 5011 adult volunteers attending vaccination centers in different regions of Colombia were enrolled in a 1-year prospective observational cohort study to evaluate the immunogenicity and effectiveness of SARS-CoV-2-based vaccines as part of a National Vaccine Program established to contain the COVID-19 pandemic. Following informed consent, 5,011 participants underwent a sociodemographic survey and PCR testing to assess SARS-CoV-2 infection. Blood samples were collected, and serum fractions were obtained from a participant subsample (n = 3441) at six-time points to assess virus-specific IgG responses to the Spike protein, its Receptor Binding Domain, and the Nucleoprotein by ELISA. Additionally, antibody-neutralizing activity was evaluated using a cPass SARS-CoV-2 neutralization kit. Most participants (95.8%; n = 4802) received between one Ad26. COV2.S (Janssen vaccine) and four vaccine doses of BNT162b2 (Pfizer/BioNTech), AZD1222 (AstraZeneca), mRNA-1273 (Moderna), CoronaVac (Sinovac), with some receiving vaccine combinations; a small group, 4.2% (n = 209), remained unvaccinated. Throughout the study, only 8.76% (n = 439) of the participants tested positive for SARS-CoV-2 by PCR. Notably, all participants seroconverted for IgG antibodies, with high seropositivity rates for S (99.8%; n = 4795), RBD (99.7%; n = 1691), and N (92.7%; n = 3072) proteins. Moreover, significant (92%-97%) neutralizing activity was observed for all four SARS-CoV-2 circulating variants. This study highlights the importance of assessing the duration of the IgG response to SARS-CoV-2 elicited by vaccination and infection, and the antibody neutralizing activity as a potential surrogate marker of protection. These findings provide important insight for further strengthening the vaccination strategies to control COVID-19.
Keywords: COVID‐19; SARS‐CoV‐2; antibody; neutralization; vaccines.